EDAP: EDAP TMS S.A. Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 10:46 AM Edap (EDAP -8.3%) plunges after announcing a registered direct placement of $12M in shares at $4 each with attached warrants for up to 1.5M additional shares at an exercise price of $4.25. Today's losses erase strong gains posted Monday on the back of positive data from a long-term study of HIFU therapy. (PR) Comment! [Healthcare, On the Move]
Monday, May 20, 11:48 AM Edap (EDAP +5.3%) posts solid gains after saying minimally invasive, high-intensity focused ultrasound (HIFU) therapy demonstrates "encouraging cancer-specific survival rates in patients with localized prostate cancer." The company cites data culled from a large, long-term study of "mobility and oncologic outcomes" conducted by two doctors at Edouard Herriot Hospital in France. (PR) Comment! [Healthcare, On the Move]
Thursday, May 16, 11:45 AM Edap (EDAP -3.5%) falls after missing the one available analyst EPS estimate, although revenues beat by a slim margin and rise 23% Y/Y on "strong demand for [the company's] innovative lithotripsy product range in key global markets." CEO Marc Oczachowski says the "FDA process for Ablatherm-HIFU is on track." Profit margins fall 220 basis points Y/Y on a negative yen impact and operating expenses increase 9.7% on "continued regulatory expenses associated with the PMA filing for Ablatherm-HIFU, as well as sales and marketing investments." (PR) 4 Comments [Healthcare, Earnings, On the Move]
Thursday, May 16, 11:32 AM EDAP (EDAP): Q1 EPS of -€0.21 or -$0.27 misses by $0.22. Revenue of €5.9M or $7.8M (+23% Y/Y) beats by $0.15M. (PR) Comment! [Healthcare, Earnings]
Thursday, April 11, 8:49 AM Edap (EDAP) releases preliminary Q1 top line results of $7.8M, representing a 23% Y/Y increase — the one available analyst estimate has revenue at $7.65M for Q1. Comment!
Tuesday, April 2, 2:53 PM Shares of Edap (EDAP -5.2%) take a hit after its Q4 missed on top line estimates. Earlier today the company reported a loss of €0.06 or $0.08 per share, in line with the Street consensus for a loss of $0.08 loss per share. Revenues were €9.4M, or $12.3M, slightly beating estimates of $12.15M. In the same period last year, the company reported an EPS loss of €0.04 or $0.05 on revenues of €7.5M or $10.1M. 1 Comment [Earnings, Healthcare, On the Move]
Tuesday, April 2, 7:26 AM EDAP (EDAP): Q4 EPS of -EUR0.06. Revenue of $12.3M (+25.3% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 28, 11:51 AM Edap (EDAP +3.4%) gains after saying the FDA has given the thumbs-up on a pre-market approval application for its Ablatherm Integrated Imaging HIFU device, a high-intensity utrasound treatment for low-risk, localized prostate cancer. 1 Comment [Healthcare, Global & FX, On the Move]
Thursday, March 7, 9:36 AM The FDA accepts Edap's (EDAP +9.5%) pre-market approval application for its ultrasound device for treating low-risk, localized prostate cancer. The next step for the product, which is called the Ablatherm Integrated Imaging HIFU (High Intensity Focused Ultrasound), is the filing review. Both assessments look at the completeness of the application and not the clinical outcomes of the study. (PR) Comment! [Healthcare, On the Move]
Thursday, March 7, 9:10 AM Premarket gainers: HIMX +36%. NQ +17%. CIEN +15%. MTSL +12%. FNSR +9%. HZNP +8%. EDAP +8%. WFR +7%. DANG +6%. INFN +6%. JDSU +6%. INVE +6%. MLNX +5%.
Losers: JRCC -14%. AV -11%. SCTY -8%. PETM -8%. DRYS -7%. NBG -5%. Comment! [On the Move]
Monday, February 25, 3:45 PM ADR's of Edap TMS (EDAP +17.8%) jump today on the back of a postitive article in Seeking Alpha, calling it the 'holy grail' in the fight against prostate cancer. Its recent disclosure of test data on its Ablatherm-HIFU - which uses High-Intensity Focused Ultrasound to eviscerate localized prostate cancer - shows it's testing progress has advanced well beyond the stage of laboratories and mice, and is highly likely to receive FDA approval. Comment! [Healthcare, Global & FX, On the Move]
Friday, February 22, 12:53 PM Midday top 10 gainers: WBMD +25%. EDAP +24%. PSDV +24%. ARUN +22%. BLOX +17%. SSTK +16%. FIRE +15%. B +15%. AVG +12%. RKUS +12%.
Midday top 10 losers: ETRM -20%. MMSI -19%. WIFI -18%. FRO -14%. NVGN -12%. CBMX -12%. VOLC -11%. GMXR -16%. RCKY -11%. REED -11%. Comment! [On the Move]
Friday, February 22, 12:23 PM EDAP TMS SA (EDAP +19.7%) pops today after earlier reporting test data showing high survival and salvage rates for patients given its high-intensity focused ultrasound therapy to treat prostate cancer. The study was electronically published in the Journal of Urology, the Official Journal of the American Urological Association. Comment! [Healthcare, Global & FX, On the Move]
Monday, February 4, 12:45 PM Midday top 10 gainers: HPTX +31%. APKT +22%. EBOD +16%. PGRX +15%. SONS +14%. PC +11%. EDAP +9%. ORRF +10%. HMY +9%. TAOM +9%.
Midday top 10 Losers: INUV -13%. CLSN -13%. SED -12%. CYTK -8%. VVI -9%. CTC -8%. PRIS -8%. PERI -8%. BLIN -8%. CFBK -8%. Comment! [On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Friday, February 1, 11:21 AM EDAP TMS SA (EDAP +15.5%) gets a pop after submitting its Pre-Market Approval Application to the FDA for Ablatherm-HIFU, a high intensity ultrasound for the treatment of low risk, localized prostate cancer. Included in EDAP's submission is positive data from its Phase 3 clinical trials and encouraging statistics from its worldwide database of treatment information and follow-up data from patients who have already undergone the therapy. Comment! [Healthcare, On the Move]

EDAP EDAP TMS S.A.

EDAP

EDAP TMS S.A.